Finally, we examined the combined effect of reparixin with tamoxifen, fulvestrant, and two CDK4/6 inhibitors such as palbociclib and ribociclib which are currently being used in treatment of endocrine resistant breast cancer therapy [23]. This evidence concerns the gene CDK4 and breast cancer.